drugset / Trial / NCT00381953

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

NCT00381953

Phase 3 Completed 33 enrolled Foundation for Liver Research
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Timeline

Start
2003-02
Primary completion
2006-04
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Comparator Peginterferon alfa-2a Protein / enzyme biologic 360 ug
Comparator interferon alfa Protein / enzyme biologic 4.5 iu
Comparator interferon alfa Protein / enzyme biologic 9 iu
Comparator Ribavirin Small molecule